Zhong Lu

Zhong Lu


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 February 2025 in Scientific Reports
Verified
Journal Article
Open access
PDF file
JYJianhang You
Jianhang You
QYQing Yu
Qing Yu
RCRonghui Chen
Ronghui Chen
JLJianlin Li
Jianlin Li
TZTao Zhao
Tao Zhao
ZLZhong Lu
Zhong Lu
Lung adenocarcinoma (LUAD) is the most common subtype of lung cancer. Despite advances in treatment, the prognosis remains poor due to late diagnosis. Cuproptosis (driven by copper ion accumulation) and disulfidptosis (driven by disulfide bond accumulation) are novel forms of programmed cell death, closely linked to tumor initiation, progression, and resistance. However, the specific roles of these mechanisms in LUAD remain inadequately studied. This study integrated multi-omics data from TCGA and GEO databases to systematically evaluate the differential expression and prognostic significance of copper and disulfide-related genes (DCRGs), identify two DCRG molecular subtypes, and construct a DCRG scoring model based on four key genes. Multi-omics analysis results revealed that the DCRG score not only accurately predicts prognosis in LUAD patients but is also closely associated with immune cell infiltration patterns and EGFR inhibitor responses. RT-qPCR validated the high expression of FURIN and RHOV in LUAD cells, supporting their role as potential therapeutic targets. Further Mendelian randomization analysis confirmed the causal relationship between FURIN and LUAD development. These findings provide novel biomarkers for the prognosis evaluation of LUAD based on cuproptosis and disulfidptosis mechanisms and offer a theoretical basis for targeting FURIN in LUAD treatment.

30 June 2025 in Molecular Diversity
Verified
Journal Article
Closed access
PDF file
JYJianhang You
Jianhang You
JYJianmin You
Jianmin You
YCYuyu Chen
Yuyu Chen
RCRonghui Chen
Ronghui Chen
ZLZhong Lu
Zhong Lu
TZTao Zhao
Tao Zhao

1 January 2026 in Journal of Cancer
Verified
Journal Article
Open access
PDF file
YYYanan Yu
Yanan Yu
XZXiuxiu Zhang
Xiuxiu Zhang
XMXiaolin Ma
Xiaolin Ma
JRJiao Ren
Jiao Ren
JZJinglei Zhang
Jinglei Zhang
JLJiaqiu Li
Jiaqiu Li
Immune checkpoint inhibitors are effective treatments for many tumors. However, existing biomarkers can benefit only a small selection of colorectal cancer patients. Super-enhancers are associated with various tumor characteristics. We wondered whether super-enhancer-related genes could be novel biomarkers for immunotherapy. We screened super-enhancer-related genes that were highly correlated with immune infiltration through weighted gene co-expression network analysis on the basis of chromatin immunoprecipitation sequencing data. A prognostic risk signature was established using least absolute shrinkage and selection operator and cox regression models. By analyzing the correlations between the expression of model genes and the immunophenotypic and microsatellite instability scores, we determined that PLAU and GSDMC expression had high predictive value for immunotherapy efficacy. Moreover, we predicted the sensitivity of the PLAU and GSDMC proteins to drugs by virtual docking. Finally, we validated the effect of the super-enhancer activity on PLAU and GSDMC expression. Overall, our study identified super-enhancer-based biomarkers for predicting survival and immunotherapy efficacy in colorectal cancer.

30 April 2026 in Lipids in Health and Disease
Verified
Journal Article
Open access
PDF file
HLHaobin Liu
Haobin Liu
YWYuxiao Wu
Yuxiao Wu
HSHaoyu Sun
Haoyu Sun
QSQunyu Sun
Qunyu Sun
MWMingguang Wang
Mingguang Wang
ZLZhong Lu
Zhong Lu
Glioma recurrence after surgery remains prevalent, significantly impacting patient survival. Tumor progression is closely linked to metabolic reprogramming

5 May 2026 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
YZYujian Zhang
Yujian Zhang
YZYu Zhang
Yu Zhang
JYJianhang You
Jianhang You
ZLZhong Lu
Zhong Lu
TZTao Zhao
Tao Zhao
Cancer-associated fibroblasts (CAFs) are important stromal cells in the tumor microenvironment of lung adenocarcinoma (LUAD). This review discusses the different cellular sources of CAFs and the main signaling pathways involved in fibroblast-to-CAF transition, with attention to the biological settings that are especially relevant in LUAD. It further discusses CAF heterogeneity not only in terms of functional subtypes, but also from the perspective of dynamic cell states shaped by spatial niche, intercellular communication, and therapy-related stress. On this basis, we outline how distinct CAF states contribute to extracellular matrix remodeling, metabolic reprogramming, invasion and metastasis, angiogenesis, immunosuppression, and therapeutic resistance in LUAD. Particular attention is given to the treatment relevance of CAFs in driver-defined disease settings, where stromal programs may influence responses to targeted therapy and immunotherapy in a context-dependent manner. We also address the main obstacles to CAF-targeted strategies, particularly heterogeneity, plasticity, and functional compensation, and point to possible directions based on precise subtyping, functional modulation, and rational combination therapy. This review thus offers a LUAD-specific perspective for understanding CAF biology and for guiding more precise stromal intervention strategies.